Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-706, Alveltamig, and Atezolizumab in First-Line Extensive Stage-Small Cell Lung Cancer
NCT07895043Phase 2Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2026
- Primary completion
- Dec 2031
01
Overview
A Phase 2 trial of turmetabart adizutecan in small cell lung cancer (SCLC), sponsored by AbbVie Inc.. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
turmetabart adizutecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07895043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07895043.